Control Clin Trials. 2002 Feb;23(1):93-9.

Double placebo design in a prevention trial for Alzheimer's disease.

Martin BK, Meinert CL, Breitner JC; ADAPT Research Group.

Source

Department of Epidemiology, Center for Clinical Trials, Bloomberg School of Hygiene and Public Health, The Johns Hopkins University, 615 N. Wolfe Street, Baltimore, MD 21205, USA. bmartin@jhsph.edu

Abstract

The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) is designed to compare two nonsteroidal anti-inflammatory agents against placebo. A placebo control for two active treatments can be achieved in several ways, each of which may have different implications for the logistics of drug supply, enrollment, adherence to treatment, and the validity of specific treatment comparisons. The authors outline the placebo designs considered in ADAPT, discuss their advantages and disadvantages, and provide their rationale for and the consequences of the selection of the double placebo design.

PMID:: 11852171; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Anti-Inflammatory Agents

Grant Support

U01 AG 15477/AG/NIA NIH HHS/United States

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Related citations

Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). [Alzheimers Dement. 2008]
Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
Meinert CL, Breitner JC. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S7-S14. Epub 2007 Dec 21.
Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. [Alzheimers Dement. 2009]
Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results.
ADAPT Research Group, Meinert CL, McCaffrey LD, Breitner JC. Alzheimers Dement. 2009 Mar; 5(2):93-104.
Review [The possible suppression of Alzheimer's disease by nonsteroidal anti-inflammatory drugs]. [Ned Tijdschr Geneeskd. 2002]
Review [The possible suppression of Alzheimer's disease by nonsteroidal anti-inflammatory drugs].
de Jong D, Jansen RW, Verbeek MM, Kremer HP. Ned Tijdschr Geneeskd. 2002 Nov 2; 146(44):2074-8.
Review Cholinesterase inhibitors for Alzheimer's disease. [Cochrane Database Syst Rev. 2006]
Review Cholinesterase inhibitors for Alzheimer's disease.
Birks J. Cochrane Database Syst Rev. 2006 Jan 25; (1):CD005593. Epub 2006 Jan 25.
A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics. [Clin Trials. 2008]
A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics.
Sano M, Jacobs D, Andrews H, Bell K, Graff-Radford N, Lucas J, Rabins P, Bolla K, Tsai WY, Cross P, et al. Clin Trials. 2008; 5(5):523-33.

See reviews... See all...

Cited by 6 PubMed Central articles

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. [Neuron. 2011]
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.
Golde TE, Schneider LS, Koo EH. Neuron. 2011 Jan 27; 69(2):203-13.
Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. [Alzheimers Dement. 2009]
Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results.
ADAPT Research Group, Meinert CL, McCaffrey LD, Breitner JC. Alzheimers Dement. 2009 Mar; 5(2):93-104.
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. [Arch Neurol. 2008]
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. Arch Neurol. 2008 Jul; 65(7):896-905. Epub 2008 May 12.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Double placebo design in a prevention trial for Alzheimer's disease.
Double placebo design in a prevention trial for Alzheimer's disease.
Control Clin Trials. 2002 Feb ;23(1):93-9.

PubMed
A novel protein complex in membrane rafts linking the NR2B glutamate receptor an...
A novel protein complex in membrane rafts linking the NR2B glutamate receptor and autophagy is disrupted following traumatic brain injury.
J Neurotrauma. 2009 May ;26(5):703-20.

PubMed
Exposure to mosquito coil smoke may be a risk factor for lung cancer in Taiwan.
Exposure to mosquito coil smoke may be a risk factor for lung cancer in Taiwan.
J Epidemiol. 2008 ;18(1):19-25.

PubMed
Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and ...
Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction.
Biochem Pharmacol. 2009 Oct 1 ;78(7):756-65. Epub 2009 Jun 18 .

PubMed
Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm...
Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background.
J Clin Invest. 2003 Apr ;111(7):1029-37.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: